01—Abstract
Summary
Summary of the 10-K filed March 15, 2004. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific's 2003 10-K shows a company in transition, with growth driven by its TAXUS paclitaxel-eluting coronary stent.
Net sales rose 19% (14% at constant currency) to $3,476 milliona from $2,919 million, and gross margin expanded 220 basis points to 72.4%. Net income was $472 million, or $0.56 per diluted share, versus $373 million ($0.45) in 2002. Operating cash flow was a solid $787 million, and EBITDA reached $879 million.
Management guided to significant revenue, earnings, and cash flow growth in 2004 as TAXUS launched in the U.S. in Q1 2004, and noted the company is one of only two drug-eluting stent products in the U.S. market. The filing also highlights meaningful risks. The U.S. drug-eluting stent market is becoming more competitive after Guidant and Johnson & Johnson's Cordis alliance, and physician adoption, pricing, and inventory management remain uncertain.
Boston Scientific carries extensive patent litigation with Johnson & Johnson/Cordis, Medinol, Medtronic, and others, and it settled its disputes with Guidant in February 2004. Balance sheet leverage rose: net debt increased to $973 millionb from $658 million, largely to fund TAXUS, acquisitions, strategic alliances, and a $570 million share buyback.
The company also disclosed that the U.S. Department of Justice investigation continues, with the company and two senior officials identified as targets of a federal grand jury, which could extend into mid-2004 or beyond. For investors, the central question is whether TAXUS can convert its strong early international share into durable U.S. leadership and margin expansion, weighed against rising competition, litigation exposure, and the open DOJ investigation.
02—Key points
Key Highlights
- Net sales grew 19% to $3,476 million in 2003 (14% at constant currency), driven largely by roughly $200 million in TAXUS sales in Europe and Inter-Continental markets.
- Gross margin expanded 220 basis points to 72.4% of net sales, supported by operating cost improvements, a richer mix of higher-margin coronary stents, and the elimination of 2002 global operations costs.
- Net income rose to $472 million ($0.56 per diluted share) from $373 million ($0.45) in 2002, though 2003 results included $49 million in after-tax charges.
- Management expects significant growth in 2004 following the Q1 2004 U.S. launch of TAXUS; about 50% of U.S. stent procedures had already converted to drug-eluting stents by year-end 2003.
- Net debt increased to $973 million from $658 million, as the company borrowed to fund TAXUS manufacturing, acquisitions, strategic alliances (about $325 million), and repurchases of 22 million shares (about $570 million).
- Litigation remains significant: multiple patent suits with Johnson & Johnson/Cordis, Medinol, and Medtronic, a Guidant settlement reached February 2004, and an open U.S. Department of Justice grand jury investigation in which the company is a named target.
- R&D spending rose to about $452 million (13% of sales), with a 2003 focus on the TAXUS program and next-generation Liberte and Express2 stent platforms.
03—Questions
Frequently Asked Questions
Why did Boston Scientific's sales and margins grow so strongly in 2003?
Sales growth was driven mainly by the TAXUS paclitaxel-eluting stent, which launched in Europe and Inter-Continental markets in early 2003 and generated about $200 million in sales. Gross margin also improved because of cost savings from its global operations strategy and a shift toward higher-margin coronary stents.
What is the main growth catalyst for 2004?
The main catalyst is the U.S. launch of the TAXUS drug-eluting stent in the first quarter of 2004. Management expects significant growth in revenue, earnings, and cash flow, and it expects gross margin and the effective tax rate, which it estimates at about 24%, to improve as TAXUS volumes rise.
How much did the company's debt and cash position change, and why?
Net debt rose to $973 million from $658 million. Gross debt increased to $1,725 million, mainly from commercial paper used to fund TAXUS inventory and capacity, acquisitions, strategic alliances, and a $570 million share repurchase. Operating cash flow of $787 million partly offset these outlays.
What are the most important risks to the TAXUS opportunity?
Key risks include slower physician adoption, especially in Europe; increased competition, including Cordis's partnership with Guidant and future entrants in Japan and the U.S.; declining average selling prices; TAXUS manufacturing disruptions or inventory mismatches; and adverse outcomes in the extensive patent litigation, which could limit sales or require material damages.
Does the Department of Justice investigation pose a material threat?
The filing states that the company and two senior officials are targets of a federal grand jury investigation relating to the NIR ON Ranger recall and the company's relationship with Medinol. No charging decision has been made, and the investigation could continue into mid-2004 or beyond. The company believes it acted responsibly, but the outcome cannot be assured, so this is a material uncertainty for investors.
04—Continue